SG 9700934-4

IPOS'S COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/569, 33/576, C07K 14/02, 16/34 — A1

(11) International Publication Number: WO 96/07915

(43) International Publication Date: 14 March 1996 (14.03.96)

(21) International Application Number: PCT/GB95/02067

(22) International Filing Date: 1 September 1995 (01.09.95)

(30) Priority Data:
9417850.6 2 September 1994 (02.09.94) GB

(71) Applicant (*for all designated States except US*): IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY & MEDICINE [GB/GB]; Sherfield Building, Imperial College, London SW7 2AZ (GB).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): HILL, Adrian, Vivian, Sinton [IE/GB]; Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DU (GB). THURSZ, Mark, Richard [GB/GB]; Hepatology Unit, Academic Department of Medicine, St. Mary's Hospital Medical School, London W2 1PG (GB). THOMAS, Howard, Christopher [GB/GB]; Hepatology Unit, Academy Department of Medicine, St. Mary's Hospital Medical School, London W2 1PG (GB).

(74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, 30 John Street, London WC1N 2DD (GB).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PREDICTIVE TEST FOR HEPATITIS-B RESISTANCE

(57) Abstract

Methods of identifying resistance to Hepatitis B infection are disclosed, as well as peptides capable of modifying immune response and methods of treating Hepatitis B.